Use of MRI and PET for Assessing Disease Activity in Takayasu’s Arteritis

Learn more about:
Related Clinical Trial
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis Comparison of Tofacitinib and Methotrexate in Takayasu’s Arteritis A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis A Pilot Study in Severe Patients With Takayasu Arteritis. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis The Registry Study of Takayasu Arteritis in East China Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases A Registry Study on Biomarkers of Takayasu’s Arteritis (ARSBTA) Infliximab Biosimilar in Takayasu’s Arteritis Exercise in Juvenile Takayasu Disease Pulmonary Artery Involvement in Takayasu’s Arteritis Anti-inflammatory Treatment for Inactive Takayasu Arteritis Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Aerobic Capacity and Strength Exercise in Takayasu’s Arteritis Use of MRI and PET for Assessing Disease Activity in Takayasu’s Arteritis Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu’s Arteritis Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis Registration Study of Takayasu’s Arteritis in China Determining Disease Activity Biomarkers in Individuals With Takayasu’s Arteritis Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging China Takayasu Arteritis Registry (CTA Registry) Takayasu Arteritis Clinical Trial in China

Brief Title

Use of MRI and PET for Assessing Disease Activity in Takayasu's Arteritis

Official Title

VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-vessel Vasculitis (Takayasu's Arteritis):Development as Clinical Trial Outcome Measures

Brief Summary

      Assessing disease activity in people with Takayasu's arteritis is difficult, as most people
      with the disease do not exhibit visible, measurable symptoms. Combination positron emission
      tomography/computed axial tomography (PET/CT) is a particularly sensitive, accurate scanning
      method that may improve researchers' ability to evaluate people with the disease. This study
      will determine the effectiveness of PET/CT in assessing disease activity in people with
      Takayasu's arteritis.

Detailed Description

      Takayasu's arteritis is a rare inflammatory disease that affects the aorta and its branches.
      The disease is much more common in females than in males, and disease onset typically occurs
      between the ages of 15 and 30. People with this disease often experience general discomfort,
      fatigue, fever, night sweats, weight loss, and joint pain. In the late stages of the disease,
      weak arterial walls may lead to aneurysms. Many patients do not exhibit any visible symptoms
      until this point, however. Because many people with Takayasu's arteritis do not have overt
      disease symptoms, the assessment of disease activity is difficult. Laboratory tests can help,
      but are often unreliable. Novel approaches to assessing disease activity are urgently needed
      to enhance and facilitate research on Takayasu's arteritis. This study will determine the
      effectiveness of combination positron emission tomography/computed axial tomography (PET/CT)
      in assessing disease activity in people with Takayasu's arteritis.

      Participants in this study will enroll while their disease is active. The first PET/CT scan
      will take place upon study entry, while there is active disease. Participants will have a
      second PET/CT scan 3 months later, and a third scan 3 months after that if there is still
      active disease present. Participants will have a maximum of 3 scans unless a scan needs to be
      repeated because of technical failures, though this does not often happen. If there is no
      active disease at the time of the second scan, a third scan will not be done. All PET/CT
      scans will be scheduled within 10 days of participants' routine MRI scans. This study will
      not require any follow-up visits.

Study Type


Primary Outcome

Disease activity


Takayasu Arteritis


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

August 2008

Completion Date

September 30, 2018

Primary Completion Date

September 30, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of Takayasu's arteritis, as defined by the VCRC Longitudinal Study #5503

          -  Currently enrolled in the VCRC Longitudinal Study #5503

          -  Active disease has occurred in conjunction with a disease relapse within 2 weeks
             before study entry (A detailed definition of "active disease" is available in the
             study protocol.)

          -  Willing and able to comply with the schedule for imaging studies and follow-up

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Unable to comply with study guidelines

          -  Unable to safely undergo MRI scanning




18 Years - N/A

Accepts Healthy Volunteers



Peter A. Merkel, MD, MPH, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Peter Merkel


 Office of Rare Diseases (ORD)

Study Sponsor

Peter A. Merkel, MD, MPH, Study Chair, University of Pennsylvania

Verification Date

October 2018